Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol
Introduction Enzalutamide and abiraterone acetate plus prednisolone (AAP) are used in combination with androgen-deprivation therapy to further suppress the androgen stimulation of metastatic castration-resistant prostate cancer (mCRPC). First-line mCRPC treatment with enzalutamide and AAP yields sim...
Zapisane w:
| Główni autorzy: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
BMJ Publishing Group
2019-09-01
|
| Seria: | BMJ Open |
| Dostęp online: | https://bmjopen.bmj.com/content/9/9/e030218.full |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|